Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Loren who wrote (1532)	8/19/1998 12:11:00 PM
From: Sylvester	Respond to of 4140

Love it when you guys Rainer & Loren talk dirty. Good job!! Haven't bugged my optho sources in a while wo I made a few calls. Some sold shares at $8 last week but really no significant volume. Would buy again at $6.25. What's missing is all this new volume based on the NASDAQ listing. Probably the earning report took the steam out of the possibilities. I might have mentioned that a friend of mine writes an analysis program for a large brokerage. No one programmer writes enough of the program to see how it works but all know more or less the intent. Basically, the program signals buying opportunities for institutional investors and mutual funds. If their determination echo those of Rainer and Loren, and I see no reason why they would not, don't expect to see the volume we're looking for. This same friend, who owns SNRS at $5.50 or so, likes the stock long term in theory but suggests waiting until volume picks up on the upside (easy call) and the stock breaks through $8.50, a long way off. The stock should back off at this point but volume will remain strong as timed accumulation moves the stock up slowly towards the promised land. When? Not that soon. General tension about which way the market in general is heading keeps SNRS down. Except for info on the progress of the trials, there is no new big news scheduled for a while. He tells me that large investors don't mind getting in late, and it's unwise to purchase a small issue in high volume untill overall volume over several days in 40% higher than the average volume thus far. This combined with a very narrow daily trading range are two of the criteria needed for a buying signal. He says there are 170 others in all in the program, but only someone on the inside of the mutual fund weights how each criteria is prioritized. The only funds he thinks may buy SNRS soon are biotech funds needing to exchange one stock for another. In this situation, a pending FDA approval combined with market potential are highly weighted criteria. In general the charts may be indicating that we'll be a long time languishing between just above $6 and just below $8 where traders may make some money but others may just exit the stock for a while and take advantage of more current opportunities. I for one, am sitting but admit it's becomming more uncomfortable in the short and now mid term. Any opinions?

To: Loren who wrote (1532)	8/19/1998 12:14:00 PM
From: Joe	Read Replies (1) \| Respond to of 4140

Pasted from Raging Bull thread: *** By: jpublic89 Reply To #530 by snrs7 Wednesday, 19 Aug 1998 , 10:54 AM EDT Post # of 537 SNRS7, yes. The stock price will move up before FDA approval, IMO. There are a number of events that will cause the price to rise. This is what I foresee. 1. The first event could be a road show where Russ Trenary, the CEO, articulates the SNRS story to institutional investors, brokers and analysts in NY, Boston, and elsewhere. It was rumored on one of the threads that there would be a road show in September. I don't know if this is anything more than a rumor but that timing would make sense. Based on admr's recent post of Vickers data, we only have 3% institutional ownership prior to NASDAQ listing. I'm sure there was some upon listing, but there is room for a lot more institutions to get into a "baby VISX." 2. There is the ESCRS (European Society of Cataract & Refractive Surgery) meeting in Nice, France, September 6th through the 9th, which, like the ASCRS, is a major meeting. I would expect to see news from that meeting by way of more papers published. Further, I expect there will be sales at that meeting. 3. There is a symposia in NYC October 3rd and 4th put on by Ocular Surgery News that will give Wall Street types a chance to become acquainted with SNRS. 4. AAO (American Academy of Ophthalmology) will be in New Orleans, starting November 8th. This is the biggest meeting for Ophthalmology. Sunrise stock price always moves up at this meeting, sometimes a little, other times more. This would be a perfect time to announce the submission of the PMA. I guaranty there will be a big move in the stock if SNRS is able to pull off a submission by the Academy. Even if they don't, there will be enough evidence that the submission is imminent to cause many ophthalmologists to pour money into the stock. A lot of analysts, institutional types and major investors attend this meeting as well as ophthalmologists. 5. PMA submission. If it did not happen by AAO, then there will be a significant move in price when the submission occurs. 6. After the FDA reviews the PMA, there will be an announcement by FDA that the PMA has been placed on the agenda of the Ophthalmic Devices Panel. It is remotely conceivable that this could be as early as the January Panel, but it is more likely at the April panel, IMO. 7. The panel meets and SNRS will either get a recommendation to the FDA for approval or for conditional approval with more data. Recommendation will probably be conditional unless submission and data are perfect. The stock will take a big jump in price here. 8. The FDA will then either approve within several weeks to several months of the panel meeting depending on whether they need additional data from Sunrise. This news results in another big move in the stock. There are a number of other news events possible. These could include news of other indications for use and the initiation of trials, etc. From event #8 above onward, the progression of news will be about the same as what we saw for VISX since September of 1995 when they got approval. You will need to hang onto you hats for each of these events, but when per use fees overtake equipment sales, look out. This will be the Mother of all SNRS moves in price. I don't know if I will have a yacht in Boca, but I will have one somewhere on the West Coast by then. Regards, jpublic89 (Voluntary Disclosure: Position- long; ST Rating- strong buy; LT Rating- strong buy) ***